Get the Stockscreener App
1.22
2.52%
0.03
After Hours:
1.20
-0.02
-1.64%
Neurosense Therapeutics Ltd stock is traded at $1.22, with a volume of 77,199.
It is up +2.52% in the last 24 hours and up +0.00% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.19
Open:
$1.21
24h Volume:
77,199
Relative Volume:
0.12
Market Cap:
$29.80M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-2.0883
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
+4.27%
1M Performance:
+0.00%
6M Performance:
+15.09%
1Y Performance:
+7.96%
1-Day Range:
$1.18
$1.23
1-Week Range:
$1.12
$1.27
52-Week Range:
$0.80
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.22 | 29.80M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
Historical volatility pattern of NeuroSense Therapeutics Ltd. Equity Warrant visualized2025 Price Action Summary & Weekly Market Pulse Alerts - newser.com
Evaluating NeuroSense Therapeutics Ltd. with trendline analysis2025 Analyst Calls & Safe Entry Point Identification - newser.com
Smart tools for monitoring NeuroSense Therapeutics Ltd.’s price actionJuly 2025 Patterns & Daily Profit Maximizing Tips - newser.com
How NeuroSense Therapeutics Ltd. Equity Warrant stock performs in stagflationDividend Hike & Proven Capital Preservation Tips - newser.com
What institutional flow reveals about NeuroSense Therapeutics Ltd.2025 Buyback Activity & Verified Short-Term Trading Plans - newser.com
Is it too late to sell NeuroSense Therapeutics Ltd.July 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
What momentum indicators show for NeuroSense Therapeutics Ltd. stockTrade Analysis Summary & Real-Time Market Sentiment Alerts - newser.com
Using R and stats models for NeuroSense Therapeutics Ltd. Equity Warrant forecasting2025 Top Gainers & Community Verified Swing Trade Signals - newser.com
Is NeuroSense Therapeutics Ltd. stock poised for growth2025 Fundamental Recap & Daily Volume Surge Trade Alerts - newser.com
Volume spikes in NeuroSense Therapeutics Ltd. stock – what they meanTrade Risk Summary & Daily Stock Trend Watchlist - newser.com
Can a trend reversal in NeuroSense Therapeutics Ltd. lead to recoveryTrade Exit Report & Weekly Stock Breakout Alerts - newser.com
How sentiment analysis helps forecast NeuroSense Therapeutics Ltd. Equity WarrantSwing Trade & Reliable Intraday Trade Plans - newser.com
Will NeuroSense Therapeutics Ltd. stock return to pre crisis levelsJuly 2025 Volume & Daily Stock Trend Watchlist - newser.com
Using economic indicators to assess NeuroSense Therapeutics Ltd. Equity Warrant potentialWeekly Trade Review & Daily Chart Pattern Signal Reports - newser.com
Using data filters to optimize entry into NeuroSense Therapeutics Ltd.Weekly Stock Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Can NeuroSense Therapeutics Ltd. Equity Warrant rally from current levelsTrade Analysis Summary & Safe Entry Point Identification - newser.com
Real time scanner hits for NeuroSense Therapeutics Ltd. explained2025 Risk Factors & Long-Term Safe Investment Plans - newser.com
Will NeuroSense Therapeutics Ltd. (H1Z) stock draw ESG focused fundsInsider Selling & Free Daily Entry Point Trade Alerts - newser.com
Backtesting results for NeuroSense Therapeutics Ltd. trading strategiesTrade Signal Summary & AI Forecasted Entry/Exit Points - newser.com
NeuroSense Therapeutics Ltd. stock momentum explainedInsider Selling & Stock Portfolio Risk Management - newser.com
NeuroSense Therapeutics (NASDAQ:NRSN) Shares Down 1.7% – Time to Sell? - Defense World
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers - Sahm
Why NeuroSense Therapeutics Ltd. (H1Z) stock attracts wealthy investorsJuly 2025 Volume & Consistent Growth Equity Picks - newser.com
NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC - TipRanks
Neurosense Therapeutics LtdPrimeC produces statistically significant reductions in Alzheimer's disease biomarkers - MarketScreener
Heatmap analysis for NeuroSense Therapeutics Ltd. Equity Warrant and competitorsPrice Action & Daily Oversold Stock Bounce Ideas - newser.com
Will NeuroSense Therapeutics Ltd. stock continue dividend increasesJuly 2025 Closing Moves & Safe Capital Growth Stock Tips - newser.com
Why NeuroSense Therapeutics Ltd. stock is rated strong buyMarket Activity Report & Daily Profit Focused Screening - newser.com
Is NeuroSense Therapeutics Ltd. (H1Z) stock undervalued after correctionInsider Selling & High Win Rate Trade Tips - newser.com
Published on: 2025-10-05 05:10:08 - newser.com
Will NeuroSense Therapeutics Ltd. Equity Warrant stock maintain dividend yieldJuly 2025 Review & Daily Chart Pattern Signals - newser.com
Leading vs lagging indicators on NeuroSense Therapeutics Ltd. Equity Warrant performanceEarnings Risk Report & High Yield Stock Recommendations - newser.com
Published on: 2025-10-05 02:56:57 - newser.com
NeuroSense Reports Positive Initial Results for Alzheimer’s Drug Candidate - MSN
Why hedge funds are buying NeuroSense Therapeutics Ltd. Equity Warrant stock2025 Historical Comparison & Momentum Based Trading Signals - newser.com
Is NeuroSense Therapeutics Ltd. Equity Warrant stock undervalued vs historical averagesTrade Analysis Summary & Safe Capital Growth Tips - newser.com
Published on: 2025-10-03 05:13:43 - newser.com
Why NeuroSense Therapeutics Ltd. (H1Z) stock is a must watch tickerJuly 2025 Fed Impact & Real-Time Chart Pattern Alerts - newser.com
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):